• Nuclear Medicine and Molecular Imaging
• /
• 제41권3호
• /
• pp.247-251
• /
• 2007

A 38-year-old man who was diagnosed with malignant paraganglioma underwent computed tomography (CT) and I-131 metaiodobenzylguanidine (MIBG) san. CT showed extensive lymph node enlargement in right iliac area and retroperitoneum with severe hydronephrosis and mass on posterior bladder wall. However, I-131 MIBG scan didn't showed abnormal uptake. He also underwent F-18 fluorodeoxyglucose (FDG) positron emisson tomography/CT for localizing accurate tumor site. F-18 FDG PET/CT showed multiple metastases of left supraclavicular, hilar, mediastinal para-aortic, inguinal, right iliac lymph nodes, lung, vertebrae, and pelvis. There are a few reports showing that the F-18 FDG PET/CT is helpful for staging and localizing tumor site of patients who are diagnosed with negative on the MIBG scans. Thus, we report a case with paraganglioma which showed negative I-131 MIBG scan, but revealed multiple intense hypermetabolic foci in F-18 FDG PET/CT.

• 대한핵의학회지
• /
• 제6권1호
• /
• pp.41-49
• /
• 1972

The author observed the thyroid $^{131}I$ uptake rate using an intradermal injection method. The amount of activity remaining at the site of intradermal injection of 0.1 ml. of $5{\mu}Ci.\;of\;^{131}I$ in physiologic saline was measured in 79 cases of hyperthyroidism and in 24 cases of hypothyroidism. The cases had been confirmed by clinical and laboratory findings, at the department of medicine, (radioisotope clinic) Pusan National University Hospital. Twenty-nine normal control cases were examined currently by the same technique during the period from Jan. 1967 to June 1970. The following results were obtained: 1. In the normal group, the ranges and mean values of the thyroid uptake 10, 15, 20, 25, 30 and 60 minutes after intradermal $^{131}I$ injection, were $0{\sim}10%(6.33{\pm}1.63),\;0{\sim}15%(7.83{\pm}2.12),\;0{\sim}15%(8.46{\pm}2.82),\;5.1{\sim}20%(9.66{\pm}2.27),\;5.1{\sim}25%(10.47{\pm}2.52),\;5.1{\sim}30%(13.03{\pm}4.42)$. 2. In the hyperthyroid group, the ranges and mean values of the thyroid uptake 10, 15, 20, 25, 30 and 60 minutes after intradermal $^{131}I$ injection were $5.1{\sim}45%(22.25{\pm}7.04),\;10.1{\sim}50%(28.32{\pm}6.67),\;15.1{\sim}55%(34.78{\pm}11.63),\;15.1{\sim}65%(37.95{\pm}7.72),\;20.1{\sim}65%(41.49{\pm}0.05)\;and\;20.18096(48.71{\pm}12.51)$. 3. In the hypothyroid group, he ranges of thyroid $^{131}I$ uptake by intradermal $^{131}I$ injection at 10, 15, 20, 25, 30 and 60 minutes lay between 0 and 10%, and the the mean values were $4.23{\pm}1.76,\;5.08{\pm}1.68,\;5.56{\pm}1.70,\;6.02{\pm}1.75,\;6.37{\pm}1.91\;and\;6.95{\pm}2.07$. 4. In conclusion, thyroid function test using an intradermal injection method in cases of hyperthyroidism, showed characteristic values which seemed to be of diagnostic significance.

• 대한핵의학회지
• /
• 제34권4호
• /
• pp.265-275
• /
• 2000

The thyroid gland is an interesting endocrine organ where a spectrum of tumors with different behavior arise. At one end of spectrum there is differentiated thyroid carcinoma (DTC) with excellent prognosis, whereas at the other end of the spectrum is anaplastic thyroid cancer which has universally poor outcome. Radioiodine (I-131) therapy has been in use for the treatment of thyroid diseases since 1946. It was introduced by Seidlin et al. 1) Although the use of I-131 has been vouge for a long time, its use in therapy for well differentiated thyroid cancer is still controversial 2). This is because, thyroid cancers (TC) are generally slow growing tumors, with low mortality and normal spans of survival. To record recurrence and mortality, long term follow up studies over a period of two to three decades are needed to establish definite conclusions on the acceptable mode of treatment The incidence of the disease being very low a large number of cases needed to establish a meaningful statistical data is lacking as most published reports feat with small series. Here again in the problem encountered are the differing protocols for treatment with I-131, the indications for treatment which may include or exclude ablation of residual thyroid tissue, cervical nodal and distal metastases. The dosage of I-131 used for ablation of residual thyroid tissue and metastatic disease also vary. The most reliable conclusion regarding I-131 treatment are obtained from studies reported on a large series of patients followed over a period of 2 decades or more from a single institute with a more or less unchanged protocol of management.

• Nuclear Engineering and Technology
• /
• 제55권1호
• /
• pp.295-303
• /
• 2023

Whole-body counters are widely used to assess internal contamination after a nuclear accident. However, it is difficult to determine radioiodine activity due to limitations in conventional calibration phantoms. Inhaled or ingested radioiodine is heterogeneously distributed in the human body, necessitating time-dependent biodistribution for the assessment of the internal contamination caused by the radioiodine intake. This study aims at calculating counting efficiencies considering the biodistribution of ¹³¹I in whole-body counting measurement. Monte Carlo simulations with computational human phantoms were performed to calculate the whole-body counting efficiency for a realistic radioiodine distribution after its intake. The biodistributions of ¹³¹I for different age groups were computed based on biokinetic models and applied to age- and gender-specific computational phantoms to estimate counting efficiency. After calculating the whole-body counting efficiencies, the efficiency correction factors were derived as the ratio of the counting efficiencies obtained by considering a heterogeneous biodistribution of ¹³¹I over time to those obtained using the BOMAB phantom assuming a homogeneous distribution. Based on the correction factors, the internal contamination caused by ¹³¹I can be assessed using whole-body counters. These correction factors can minimize the influence of the biodistribution of ¹³¹I in whole-body counting measurement and improve the accuracy of internal dose assessment.

• 한국방사선학회논문지
• /
• 제7권3호
• /
• pp.251-257
• /
• 2013

고용량 옥소 치료 시 수평면, 수직면, 방위각에 따라 3차원적으로 방출되는 공간선량률을 측정하였다. 정확한 측정을 위해 기하학적 구조의 알루미늄 틀을 제작하여 100 cm 거리에서, 높이 (5 측정점), 방위각 (8 측정점), 시간적 간격 (6 측정점)을 각각 나누어서 분석하였다. 수직면상 공간선량률 분포는 $^{131}I$을 경구 투여 24 시간 후 환자로부터 거리 100 cm, 높이 100 cm 지점에서 환자군 평균 71.85 ${\mu}Sv/h$로 가장 높았다. 수분섭취를 통한 공간선량률 감쇠 정도를 두 그룹으로 나누어 실험하였다. $^{131}I$을 경구 투여 24시간 뒤 거리 100 cm, 높이 100 cm에서 공간선량률 분포가 A 실험군은 44.9 ${\mu}Sv/h$이고 B 실험군은 100.28 ${\mu}Sv/h$이다. A 실험군이 B 실험군과 비교하여 고용량 옥소 치료 시 수분섭취 정도에 따라 약 53 %의 피폭경감 효과를 확인하였다.

• 대한핵의학회지
• /
• 제4권2호
• /
• pp.29-39
• /
• 1970

A summary of the clinical data of the $^{131}I$-thyroid function tests and the therapeutic results of $^{131}I$ among the 2,658 patients of various thyroid diseases treated over the past 10 years from May 1960 to Oct. 1969 at the Radioisotope Clinic and Laboratory, SNUH were presented and dscussed. 1. The patients examined consisted of: 929 cases (34.9%) of diffuse toxic goiter, 762 cases (28.7%) of diffuse nontoxic goiter, 699 cases (26.3%) of nodular nontoxic goiter, 58 cases (2.2%) of nodular toxic goiter and 210. cases (7.9%) of hypothyroidism. 2. There were 300 (11.4%) male and 2358 (88.6%) female, showing a ratio of 1:8. 3. The majority of patients (79.1%) were in the 3rd-5th decades of their lives. 4. The normal ranges, diagonstic values of $^{131}I$ uptake test, 48 hrs, serum activity, BMR and main subjective symptoms of various thyroid diseases were discussed. 5. In the 579 patients among 867 cases with hyperthyroidism treated with $^{131}I$, 47.8% were confirmed to be cured completely after single therapeutic doses. 6. The complications of $^{131}I$ therapy were discussed and myxedema had developed in 6.75% of our patients. 7. The results of $^{131}I$ thyroid function tests were analysed among the 160 cases of thyroid diseases which were confirmed the diagnosis with histopathological measures.

• Journal of Radiation Protection and Research
• /
• 제32권2호
• /
• pp.45-50
• /
• 2007

본 연구는 한국인 특성에 대해 보다 신뢰할 수 있는 방사성핵종의 체내 흡수선량 평가를 위한 일환으로 $^{131}I$을 선정하여 체내 각 장기별 잔류율 및 소변 일일배설률을 측정하였다. 실험방법은 성인남성 28명을 대상으로 $^{131}I$을 경구 투여한 후, 시간대별(2, 4, 6, 24시간) 갑상선, 간, 위, 소장, 신장, 소변의 방사능을 측정하고 이를 이용하여 각 장기별 잔류율 및 소변 일일배설률을 산출하였다. 그 결과, $^{131}I$ 투여 24시간 후 갑상선이 평균 19.70%의 잔류율과 71.12%의 소변 일일배설률을 나타냈으며, 갑상선을 제외한 각 장기는 투여 2시간 후 최고 잔류율 및 최고 소변 일일배설률을 보이나, 이후 감소하는 경향을 보였다. 또한 잔류율이 높은 장기 순서는 갑상선을 제외하고 위, 왼쪽 신장, 간, 소장, 오른쪽 신장으로 나타났다. 본 연구를 통해 산출된 방사성옥소의 섭취 24시간 후 갑상선 잔류율 변화는 기존 30%로 보고된 ICRP-54/67 및 25% 잔류율로 보고된 ICRP-78의 자료와 차이를 나타냈다. 한국인의 특성에 맞는 체내 흡수선량 평가의 올바른 접근과 그에 따른 기초 자료의 확보는 향후 원자력 발전소의 작업 종사자 내부피폭 및 임상에서 발생 가능한 체내 피폭의 정량적 평가에 도움을 줄 수 있을 것으로 판단된다.

• Nuclear Medicine and Molecular Imaging
• /
• 제40권2호
• /
• pp.66-73
• /
• 2006

Monoclonal antibodies are designed to bind specifically to certain antigen, give therapeutic effect to the target and to be produced in large scale with homogeneity. The monoclonal antibodies conjugated with radionuclide can deliver therapeutic irradiation to the target, and showed successful results in certain malignancies, which is known as radioimmunotherapy. The target-to-background ratio depends on the antigen expression in the target and normal tissues, which is related to the therapeutic efficacy and toxicity in radioimmunotherapy. For the solid tumor beta-ray energy should be high, but lower beta energy is better for the hematological malignancies. I-l31 is widely used in thyroid cancer with low cost and high availability. Labeling monoclonal antibody with I-131 is relatively simple and reproducible. Some preclinical data for the I-131 labeled monoclonal antibodies including acute toxicity and efficacy are available from already published literatures in KIRAMS, physician sponsored clinical trial protocols using Rituximab, KFDA approved anti-CD20 chimeric monoclonal antibody and I-131 were approved by KFDA and currently are ongoing.

• 대한두경부종양학회지
• /
• 제17권2호
• /
• pp.174-178
• /
• 2001

Background and Objective: Percutaneous ethanol injection therapy has been used in the treatment of the benign thyroid diseases. Although the reported side-effects of the therapy was mild and transient, some side-effects including local or radiating pain are troublesome to the patients. Radioactive iodine-131($Ra-^{131}I$) also has been effectively and safely used for management of the benign thyroid diseases. So we developed the percutaneous intranodular injection therapy of $Ra-^{131}I$ as an alternative of percutaneous ethanol injection therapy. Materials and Methods: From December 1998 to October 1999, we treated 29 outpatients (25 women and 4 men, mean age: $47{\pm}12$ years). Inclusion criteria were follows; age >30 years, cytologically benign, with normal thyroid function, cold nodule on thyroid scintigram, solid or mixed natured nodules in sonographical evaluation. Nodular volume was estimated by sonography according to the ellipsoid formula. $Ra-^{131}I$(0.1mCi/ml) was administered in a single dose injection. Follow-up studies every 3 months consisted of full history, thyroid function test, and sonography. We determined the therapeutic response is effective if the volume reduction of the nodule occurred above 30%. Results: After at least 3 months follow-up, 11 patients showed effective response, 12 patients showed minimal or unchanged response and 6 patients showed progression. Although side-effects such as injection pain, febrile reaction, and hormonal changes were absent, an infectious complication in injection site was developed from 1 case. Conclusion: Although we need a more prolonged follow-up to evaluate the delayed sequelae, we can suggest that percutaneous intranodular injection therapy of $Ra-^{131}I$ may be an attractive non-surgical treatment in selected cases of benign thyroid nodules.

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1967년도 제6회 학술대회
• /
• pp.104.2-104.2
• /
• 1967